Jagsonpal Pharmaceuticals Ltd (BOM:507789)

Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript

Nov 4, 2025 / 08:30 AM GMT

Release Date Price: ₹217.1 (-3.92%)

Transcript

Key Points

Positve

Jagsonpal Pharmaceuticals Ltd (BOM:507789) reported a 10% growth in sales for the first half of FY26, demonstrating strong business fundamentals.
The company maintained a robust cash balance of INR 160 crore despite a higher dividend payout, indicating strong financial health.
The appointment of experienced leaders, Amrit Madekar as COO and Neera Bora as CFO, is expected to strengthen the company's growth and profitability.
The company successfully navigated the GST transition, offering additional credit and discounts to partners, showcasing effective management strategies.
Jagsonpal Pharmaceuticals Ltd (BOM:507789) retained its 8th position in the corporate CBM ranking, supported by the performance of key brands.

Negative

The Indian pharmaceutical market grew at 7.5%, but Jagsonpal Pharmaceuticals Ltd (BOM:507789) experienced slower growth in its key markets at 2.5% to 3%.
The GST transition posed temporary challenges, impacting the company's performance in Q2 with a largely flat performance compared to last year.
The company faces challenges in increasing MR productivity, which is currently below expectations.
There is a need for more aggressive inorganic growth strategies, but the company lacks the capability to integrate acquisitions as effectively as some competitors.
The company is cautious about entering crowded markets with new product launches, which may slow down potential growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

JGSN.NS - Jagsonpal Pharmaceuticals Ltd
Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call
Nov 04, 2025 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Jackson Pal Pharmaceutical Limited Q2 and H1 F 526 earnings conference call hosted by GoIndia Advisors LLP.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing start, then 0 on your touchtone phone. Please note this conference is being recorded. I now hand the conference over to Miss Soya.

Thank you. I'll leave it to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.